PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31464590-1	2019	BACKGROUND: THK5351 and flortaucipir tau ligands have high affinity for paired helical filament tau, yet diverse off-target bindings have been reported.	THK5351	12-19	microtubule associated protein tau	Homo sapiens	72-99
31834916-11	2019	Hippocampal atrophy was associated with both beta-amyloid and THK-5351 uptake, possibly reflecting an interaction between beta-amyloid and tau deposition in the neurodegeneration process.	THK5351	62-70	microtubule associated protein tau	Homo sapiens	139-142
31464590-2	2019	Recent data support the hypothesis that THK5351 binds to monoamine oxidase B (MAO-B) expressed from reactive astrocytes and that flortaucipir has an affinity toward MAO-A and B; however, pathological evidence is lacking.	THK5351	40-47	monoamine oxidase B	Homo sapiens	57-76
31464590-2	2019	Recent data support the hypothesis that THK5351 binds to monoamine oxidase B (MAO-B) expressed from reactive astrocytes and that flortaucipir has an affinity toward MAO-A and B; however, pathological evidence is lacking.	THK5351	40-47	monoamine oxidase B	Homo sapiens	78-83
31464590-10	2019	CONCLUSIONS: Our findings add pathological evidence that increased THK5351 uptake in sporadic CJD patients might be caused by an off-target binding driven by its high affinity for MAO-B.	THK5351	67-74	monoamine oxidase B	Homo sapiens	180-185
29143870-2	2018	Recently, tau positron emission tomography tracers such as [18F] AV-1451 and [18F] THK5351 have been developed to detect tau deposition in vivo.	THK5351	83-90	microtubule associated protein tau	Homo sapiens	10-13
31795034-0	2019	Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy.	THK5351	66-73	monoamine oxidase B	Homo sapiens	14-33
31795034-2	2019	However, the interpretation of [18F]THK5351 uptake has been shown to be confounded by high monoamine oxidase B (MAO-B) availability across the brain in AD.	THK5351	36-43	monoamine oxidase B	Homo sapiens	91-110
31795034-2	2019	However, the interpretation of [18F]THK5351 uptake has been shown to be confounded by high monoamine oxidase B (MAO-B) availability across the brain in AD.	THK5351	36-43	monoamine oxidase B	Homo sapiens	112-117
31795034-9	2019	CONCLUSIONS: Similar to AD, the interpretation of [18F]THK5351 uptake in PSP is likely confounded by off-target binding to MAO-B binding sites.	THK5351	55-62	monoamine oxidase B	Homo sapiens	123-128
29958546-6	2018	Regional [18F]THK5351 standardized uptake value ratio (SUVR) in antemortem PET was significantly correlated with monoamine oxidase-B (MAO-B) level, reactive astrocytes density, and tau pathology at postmortem examination.	THK5351	14-21	monoamine oxidase B	Homo sapiens	113-132
29958546-6	2018	Regional [18F]THK5351 standardized uptake value ratio (SUVR) in antemortem PET was significantly correlated with monoamine oxidase-B (MAO-B) level, reactive astrocytes density, and tau pathology at postmortem examination.	THK5351	14-21	monoamine oxidase B	Homo sapiens	134-139
29958546-6	2018	Regional [18F]THK5351 standardized uptake value ratio (SUVR) in antemortem PET was significantly correlated with monoamine oxidase-B (MAO-B) level, reactive astrocytes density, and tau pathology at postmortem examination.	THK5351	14-21	microtubule associated protein tau	Homo sapiens	181-184
29958546-7	2018	In in vitro autoradiography, specific THK5351 binding was detected in the area of antemortem [18F]THK5351 retention, and binding was blocked completely by a reversible selective MAO-B inhibitor, lazabemide, in brain samples from these patients.	THK5351	38-45	monoamine oxidase B	Homo sapiens	178-183
29958546-8	2018	In conclusion, [18F]THK5351 PET signals reflect MAO-B expressing reactive astrocytes, which may be associated with tau accumulation in PSP.	THK5351	20-27	monoamine oxidase B	Homo sapiens	48-53
29958546-8	2018	In conclusion, [18F]THK5351 PET signals reflect MAO-B expressing reactive astrocytes, which may be associated with tau accumulation in PSP.	THK5351	20-27	microtubule associated protein tau	Homo sapiens	115-118
28864633-4	2018	Results: Regional in vivo 18F-THK5351 retention was significantly correlated with the density of tau aggregates in the neocortex and monoamine oxidase-B in the whole brain, but not correlated with that of insoluble amyloid-beta.	THK5351	30-37	microtubule associated protein tau	Homo sapiens	97-100
28864633-4	2018	Results: Regional in vivo 18F-THK5351 retention was significantly correlated with the density of tau aggregates in the neocortex and monoamine oxidase-B in the whole brain, but not correlated with that of insoluble amyloid-beta.	THK5351	30-37	monoamine oxidase B	Homo sapiens	133-152
29143870-2	2018	Recently, tau positron emission tomography tracers such as [18F] AV-1451 and [18F] THK5351 have been developed to detect tau deposition in vivo.	THK5351	83-90	microtubule associated protein tau	Homo sapiens	121-124
27794115-0	2016	In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET.	THK5351	70-77	microtubule associated protein tau	Homo sapiens	25-28
29542297-0	2018	Case of progressive supranuclear palsy detected by tau imaging with [18 F]THK-5351 before the appearance of characteristic clinical features.	THK5351	74-82	microtubule associated protein tau	Homo sapiens	51-54
28890300-0	2017	Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer"s disease.	THK5351	44-51	microtubule associated protein tau	Homo sapiens	0-3
28890300-11	2017	Our results suggest [18F]THK5351 is reflective of tau-related AD pathology.	THK5351	25-32	microtubule associated protein tau	Homo sapiens	50-53
28359327-0	2017	Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.	THK5351	55-62	monoamine oxidase B	Homo sapiens	0-19
28359327-3	2017	Here, we tested the effects of MAO-B inhibition on 18F-THK5351 brain uptake using PET and autoradiography.	THK5351	55-62	monoamine oxidase B	Homo sapiens	31-36
28359327-14	2017	Tissue autoradiography confirmed the effects of MAO-B inhibition on 18F-THK5351 uptake.	THK5351	68-79	monoamine oxidase B	Homo sapiens	48-53
27794115-8	2016	18F-THK5351 should be considered as a promising candidate radiotracer for the in vivo imaging of tau deposits in CBS.	THK5351	4-11	microtubule associated protein tau	Homo sapiens	97-100
27794115-4	2016	RESULTS: 3H-THK5351 was able to bind to tau deposits in the postmortem brain with CBD.	THK5351	12-19	microtubule associated protein tau	Homo sapiens	40-43
26541774-3	2016	We developed a novel tau PET tracer, (18)F-THK5351, through compound optimization of arylquinoline derivatives.	THK5351	43-50	microtubule associated protein tau	Homo sapiens	21-24
27355840-1	2016	BACKGROUND: [18F]THK5351, a recently-developed positron emission tomography (PET) tracer for measuring tau neurofibrillary tangle accumulation, may help researchers examine aging, disease, and tau pathology in living human brains.	THK5351	17-24	microtubule associated protein tau	Homo sapiens	103-106
27355840-1	2016	BACKGROUND: [18F]THK5351, a recently-developed positron emission tomography (PET) tracer for measuring tau neurofibrillary tangle accumulation, may help researchers examine aging, disease, and tau pathology in living human brains.	THK5351	17-24	microtubule associated protein tau	Homo sapiens	193-196
27355840-13	2016	CONCLUSIONS: We examined THK5351, a new PET tracer for measuring tau accumulation, and compared multiple analysis methods for quantifying regional tracer uptake.	THK5351	25-32	microtubule associated protein tau	Homo sapiens	65-68
26572762-4	2016	The recent development of selective in-vivo tau PET imaging ligands including [(18)F]THK523, [(18)F]THK5117, [(18)F]THK5105 and [(18)F]THK5351, [(18)F]AV1451(T807) and [(11)C]PBB3 has provided information about the role of tau in the early phases of neurodegenerative diseases, and provided support for diagnosis, prognosis, and imaging biomarkers to track disease progression.	THK5351	135-142	microtubule associated protein tau	Homo sapiens	44-47
26541774-6	2016	The THK5351 binding amount correlated with the amount of tau deposits in human brain samples.	THK5351	4-11	microtubule associated protein tau	Homo sapiens	57-60
34305778-8	2021	Moreover, 18F-THK5351 accumulated in the bilateral globus pallidum, amygdala, caudate nuclei, and the substantia nigra of the midbrain, which were probably off-target reaction, by binding to monoamine oxidase B (MAO-B).	THK5351	14-21	monoamine oxidase B	Homo sapiens	191-210
34912209-1	2021	Introduction: We aimed to determine whether in vivo tau deposits and monoamine oxidase B (MAO-B) detection using 18F-THK5351 positron emission tomography (PET) can assist in the differential distribution in patients with corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer"s disease (AD) and whether 18F-THK5351 retention of lesion sites in CBS and PSP can correlate with clinical parameters.	THK5351	117-124	monoamine oxidase B	Homo sapiens	69-88
34912209-1	2021	Introduction: We aimed to determine whether in vivo tau deposits and monoamine oxidase B (MAO-B) detection using 18F-THK5351 positron emission tomography (PET) can assist in the differential distribution in patients with corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer"s disease (AD) and whether 18F-THK5351 retention of lesion sites in CBS and PSP can correlate with clinical parameters.	THK5351	117-124	monoamine oxidase B	Homo sapiens	90-95
34912209-1	2021	Introduction: We aimed to determine whether in vivo tau deposits and monoamine oxidase B (MAO-B) detection using 18F-THK5351 positron emission tomography (PET) can assist in the differential distribution in patients with corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer"s disease (AD) and whether 18F-THK5351 retention of lesion sites in CBS and PSP can correlate with clinical parameters.	THK5351	333-340	monoamine oxidase B	Homo sapiens	69-88
34912209-1	2021	Introduction: We aimed to determine whether in vivo tau deposits and monoamine oxidase B (MAO-B) detection using 18F-THK5351 positron emission tomography (PET) can assist in the differential distribution in patients with corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer"s disease (AD) and whether 18F-THK5351 retention of lesion sites in CBS and PSP can correlate with clinical parameters.	THK5351	333-340	monoamine oxidase B	Homo sapiens	90-95
34305778-8	2021	Moreover, 18F-THK5351 accumulated in the bilateral globus pallidum, amygdala, caudate nuclei, and the substantia nigra of the midbrain, which were probably off-target reaction, by binding to monoamine oxidase B (MAO-B).	THK5351	14-21	monoamine oxidase B	Homo sapiens	212-217
34305778-10	2021	Besides, 18F-THK5351 retentions were observed in the bilateral medial temporal cortices and several cortical areas without cerebral amyloid angiopathy or prior hemorrhages, possibly where tau might accumulate.	THK5351	13-20	microtubule associated protein tau	Homo sapiens	188-191
34776443-2	2022	OBJECTIVE: Using 18F-THK5351 as a tracer that binds to both tau and MAO-B, we investigated the changes in 18F-THK5351 accumulation patterns in AD continuum individuals with positive amyloid PET consisting of cognitively normal individuals (CNp), amnestic mild cognitive impairment (aMCI), and AD and cognitively normal individuals (CNn) with negative amyloid PET.	THK5351	21-28	microtubule associated protein tau	Homo sapiens	60-63
35184428-12	2022	CONCLUSION: The results of the present study suggest that increased 18F-THK5351 uptake might be a useful predictor of poor prognosis among Abeta- aMCI patients, which might be associated with increased neuroinflammation (ClinicalTrials.gov NCT02656498).	THK5351	72-79	amyloid beta precursor protein	Homo sapiens	139-144
35210989-8	2022	However, the lack of selectivity of (18F)THK-5351 binding to both MAO-B and tau, severely limits its clinical utility as a biomarker.	THK5351	41-49	monoamine oxidase B	Homo sapiens	66-71
35210989-8	2022	However, the lack of selectivity of (18F)THK-5351 binding to both MAO-B and tau, severely limits its clinical utility as a biomarker.	THK5351	41-49	microtubule associated protein tau	Homo sapiens	76-79
34776443-2	2022	OBJECTIVE: Using 18F-THK5351 as a tracer that binds to both tau and MAO-B, we investigated the changes in 18F-THK5351 accumulation patterns in AD continuum individuals with positive amyloid PET consisting of cognitively normal individuals (CNp), amnestic mild cognitive impairment (aMCI), and AD and cognitively normal individuals (CNn) with negative amyloid PET.	THK5351	21-28	monoamine oxidase B	Homo sapiens	68-73
34776443-2	2022	OBJECTIVE: Using 18F-THK5351 as a tracer that binds to both tau and MAO-B, we investigated the changes in 18F-THK5351 accumulation patterns in AD continuum individuals with positive amyloid PET consisting of cognitively normal individuals (CNp), amnestic mild cognitive impairment (aMCI), and AD and cognitively normal individuals (CNn) with negative amyloid PET.	THK5351	21-28	2',3'-cyclic nucleotide 3' phosphodiesterase	Homo sapiens	240-243
34776443-2	2022	OBJECTIVE: Using 18F-THK5351 as a tracer that binds to both tau and MAO-B, we investigated the changes in 18F-THK5351 accumulation patterns in AD continuum individuals with positive amyloid PET consisting of cognitively normal individuals (CNp), amnestic mild cognitive impairment (aMCI), and AD and cognitively normal individuals (CNn) with negative amyloid PET.	THK5351	110-117	microtubule associated protein tau	Homo sapiens	60-63
34776443-2	2022	OBJECTIVE: Using 18F-THK5351 as a tracer that binds to both tau and MAO-B, we investigated the changes in 18F-THK5351 accumulation patterns in AD continuum individuals with positive amyloid PET consisting of cognitively normal individuals (CNp), amnestic mild cognitive impairment (aMCI), and AD and cognitively normal individuals (CNn) with negative amyloid PET.	THK5351	110-117	monoamine oxidase B	Homo sapiens	68-73
34776443-2	2022	OBJECTIVE: Using 18F-THK5351 as a tracer that binds to both tau and MAO-B, we investigated the changes in 18F-THK5351 accumulation patterns in AD continuum individuals with positive amyloid PET consisting of cognitively normal individuals (CNp), amnestic mild cognitive impairment (aMCI), and AD and cognitively normal individuals (CNn) with negative amyloid PET.	THK5351	110-117	2',3'-cyclic nucleotide 3' phosphodiesterase	Homo sapiens	240-243
32657863-4	2020	F-THK5351 reportedly binds to monoamine oxidase B highly expressed in astrocytes.	THK5351	2-9	monoamine oxidase B	Homo sapiens	30-49
34028419-1	2021	ABSTRACT: 18F-THK5351 was initially developed to target tau aggregates in neurofibrillary tangles.	THK5351	14-21	microtubule associated protein tau	Homo sapiens	56-59
33584247-2	2020	[18F]THK5351 has been known to detect reactive astrogliosis as well as tau which is accompanied by neurodegenerative changes.	THK5351	5-12	microtubule associated protein tau	Homo sapiens	71-74